A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)

NCT ID: NCT05465785

Last Updated: 2024-04-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 1000 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-07-20
• Study Completion Date: 2023-12-30

Brief Summary

This is a randomized, double-blind , non-inferiority design study, to evaluate the Immunogenicity bridging between different manufacture scales of Recombinant COVID-19 Vaccine (Sf9 Cell) in healthy population aged 18-59 years with immunization procedures 0, 21, 42 days .

Detailed Description

This is a randomized, double-blind , non-inferiority design study, to evaluate the Immunogenicity bridging between different manufacture scales of Recombinant COVID-19 Vaccine (Sf9 Cell) in healthy population aged 18-59 years with vaccination course 0, 21, 42 days. 892 subjects aged 18-59 years are recruited and randomly inoculated in a 1:1 ratio from a pilot or commercial batch of Recombinant COVID-19 Vaccine (Sf9 Cell).

Conditions

COVID-19; SARS-CoV-2 Pneumonia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Pilot batch

Three doses of Recombinant COVID-19 vaccine (Sf9 cell) at the schedule of day 0, 21，42.

Group Type: EXPERIMENTAL

Recombinant COVID-19 vaccine (Sf9 cell)

Intervention Type: BIOLOGICAL

This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified

Commercial batch

Three doses of Recombinant COVID-19 vaccine (Sf9 cell) at the schedule of day 0, 21，42.

Group Type: ACTIVE_COMPARATOR

Recombinant COVID-19 vaccine (Sf9 cell)

Intervention Type: BIOLOGICAL

This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified

Interventions

Recombinant COVID-19 vaccine (Sf9 cell)

This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Subjects aged from 18-59 years.
• Signed informed consent forms of the subjects have been obtained.
• Able and willing to comply with the requirements of the clinical trial protocol and able to complete approximately 8 months of study follow-up.
• Axillary temperature < 37.3℃. Subjects who fulfill all the required conditions for receiving the candidate vaccine as established by medical history and physical examination and determined by investigators.

Exclusion Criteria

• Positive SARS-CoV-2 antibodies (IgG or IgM) screening results.
• Positive SARS-CoV-2 Antigen screening results.
• History of COVID-19 vaccination.
• Previously diagnosed with COVID-19 infection.
• History of HIV infection.
• History or family history of convulsion, epilepsy, encephalopathy and psychosis.
• Allergy to any component of the candidate vaccine, severe allergy to vaccine in the past, and history of allergy.
• Women with positive urine pregnancy test results, pregnant, lactating women, or women who have a pregnancy plan during the study.
• Patients with acute febrile diseases and infectious diseases.
• Patients with a history of SARS.
• Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension that cannot be controlled by drugs, etc.
• Serious chronic diseases or progressive stage of a disease that cannot be steadily controlled, such as asthma, diabetes mellitus, thyroid disease, etc.
• Congenital or acquired angioedema/angioneurotic edema.
• Urticaria 1 year before receiving the candidate vaccine.
• Asplenia or functional asplenia.
• Thrombocytopenia or other coagulation disorders (which may contraindicate intramuscular injection).
• Fear of needles.
• Any immunosuppressant, antiallergic therapy, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) in the past 6 months.
• Blood products within 4 months prior to receiving the candidate vaccine.
• Any other investigational medicine(s) within 1 month prior to the candidate vaccine.
• Any live attenuated vaccine within 1 month prior to the candidate vaccine.
• Any subunit vaccine or inactivated vaccine within 14 days prior to the candidate vaccine.
• Receiving antituberculosis treatment.
• Medical, psychological, social or other factors, which in the discretion of the investigators fail to meet the requirements in the trial protocol or affect the subjects to sign the ICFs.

In this trial, the second/third vaccination may be stopped in some cases. They include systemic allergic reaction, severe hypersensitivity, or intolerable Grade 3 or above ARs after the previous dose of vaccine. If these reactions occur, the subjects should not continue to receive the second/third vaccination.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 59 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

WestVac Biopharma Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Jiangsu Provincial Center for Disease Control and Prevention

Huai'an, Jiangsu, China

Countries

China

Other Identifiers

JSVCT141

Identifier Type: -

Identifier Source: org_study_id